EP3080137A4 - Prodrug for release of cisplatin and cyclooxygenase inhibitor - Google Patents

Prodrug for release of cisplatin and cyclooxygenase inhibitor Download PDF

Info

Publication number
EP3080137A4
EP3080137A4 EP14869421.9A EP14869421A EP3080137A4 EP 3080137 A4 EP3080137 A4 EP 3080137A4 EP 14869421 A EP14869421 A EP 14869421A EP 3080137 A4 EP3080137 A4 EP 3080137A4
Authority
EP
European Patent Office
Prior art keywords
cisplatin
prodrug
release
cyclooxygenase inhibitor
cyclooxygenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14869421.9A
Other languages
German (de)
French (fr)
Other versions
EP3080137A1 (en
Inventor
Shanta Dhar
Rakesh Pathak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Georgia Research Foundation Inc UGARF
Original Assignee
University of Georgia Research Foundation Inc UGARF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Georgia Research Foundation Inc UGARF filed Critical University of Georgia Research Foundation Inc UGARF
Publication of EP3080137A1 publication Critical patent/EP3080137A1/en
Publication of EP3080137A4 publication Critical patent/EP3080137A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP14869421.9A 2013-12-12 2014-12-12 Prodrug for release of cisplatin and cyclooxygenase inhibitor Withdrawn EP3080137A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915110P 2013-12-12 2013-12-12
US201461976559P 2014-04-08 2014-04-08
PCT/US2014/069997 WO2015089389A1 (en) 2013-12-12 2014-12-12 Prodrug for release of cisplatin and cyclooxygenase inhibitor

Publications (2)

Publication Number Publication Date
EP3080137A1 EP3080137A1 (en) 2016-10-19
EP3080137A4 true EP3080137A4 (en) 2017-07-19

Family

ID=53371867

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14869421.9A Withdrawn EP3080137A4 (en) 2013-12-12 2014-12-12 Prodrug for release of cisplatin and cyclooxygenase inhibitor

Country Status (5)

Country Link
US (1) US20170190726A9 (en)
EP (1) EP3080137A4 (en)
JP (1) JP2017500315A (en)
CA (1) CA2931638A1 (en)
WO (1) WO2015089389A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242688B1 (en) * 2015-01-09 2020-01-29 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
EP3313393A4 (en) * 2015-06-23 2019-01-09 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
CN107296794A (en) * 2017-07-27 2017-10-27 中国药科大学 Amphipathic non-steroidal anti-inflammatory closes platinum nanoparticle and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130017265A1 (en) * 2009-12-16 2013-01-17 Massachusetts Institute Of Technology Particles for multiple agent delivery
CN102942594A (en) * 2012-11-14 2013-02-27 中国科学技术大学 Anti-cancer medicinal aspirin platinum complex and preparation method thereof
WO2014169007A2 (en) * 2013-04-09 2014-10-16 University Of Georgia Research Foundation Inc. Combination therapeutic nanoparticles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133515B2 (en) 2007-11-21 2012-03-13 University Of Georgia Research Foundation, Inc. Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds
EP2750662A4 (en) 2011-08-31 2015-06-24 Univ Georgia Apoptosis-targeting nanoparticles
ES2669561T3 (en) 2012-02-17 2018-05-28 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial transport of agents
US20150374714A1 (en) 2013-02-11 2015-12-31 University Of Georgia Research Foundation, Inc. Generation of functional dendritic cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130017265A1 (en) * 2009-12-16 2013-01-17 Massachusetts Institute Of Technology Particles for multiple agent delivery
CN102942594A (en) * 2012-11-14 2013-02-27 中国科学技术大学 Anti-cancer medicinal aspirin platinum complex and preparation method thereof
WO2014169007A2 (en) * 2013-04-09 2014-10-16 University Of Georgia Research Foundation Inc. Combination therapeutic nanoparticles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
QINQIN CHENG ET AL: "The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells", CHEMICAL COMMUNICATIONS - CHEMCOM., vol. 50, no. 56, 1 January 2014 (2014-01-01), pages 7427, XP055376526, ISSN: 1359-7345, DOI: 10.1039/c4cc00419a *
RAKESH K. PATHAK ET AL: "The Prodrug Platin- A : Simultaneous Release of Cisplatin and Aspirin", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 53, no. 7, 22 January 2014 (2014-01-22), pages 1963 - 1967, XP055373542, ISSN: 1433-7851, DOI: 10.1002/anie.201308899 *
See also references of WO2015089389A1 *
WILMA NEUMANN ET AL: "Conjugates of Cisplatin and Cyclooxygenase Inhibitors as Potent Antitumor Agents Overcoming Cisplatin Resistance", CHEMMEDCHEM, vol. 9, no. 6, 6 May 2014 (2014-05-06), DE, pages 1150 - 1153, XP055332788, ISSN: 1860-7179, DOI: 10.1002/cmdc.201402074 *

Also Published As

Publication number Publication date
EP3080137A1 (en) 2016-10-19
WO2015089389A8 (en) 2015-08-27
JP2017500315A (en) 2017-01-05
US20160326200A1 (en) 2016-11-10
US20170190726A9 (en) 2017-07-06
WO2015089389A1 (en) 2015-06-18
CA2931638A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
ZA201602245B (en) Inhibitors of kras g12c
HK1215029A1 (en) Covalent inhibitors of kras g12c kras g12c
HK1221660A1 (en) Acc inhibitors and uses thereof acc
HK1221659A1 (en) Acc inhibitors and uses thereof acc
HK1221661A1 (en) Acc inhibitors and uses thereof acc
EP3091008A4 (en) Kinase inhibitor and use thereof
EP2948450A4 (en) Metalloenzyme inhibitor compounds
EP3030566A4 (en) Aza-pyridone compounds and uses thereof
EP3008051A4 (en) Metalloenzyme inhibitor compounds
HK1221662A1 (en) Acc inhibitors and uses thereof acc
EP3003039A4 (en) Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
EP3030549B8 (en) Pyridazinone compounds and uses thereof
EP2952503A4 (en) Hiv replication inhibitor
EP2955024A4 (en) Release film
GB201317609D0 (en) Inhibitor compounds
EP3041826A4 (en) Triazolone compounds and uses thereof
EP3003372A4 (en) Inhibitors of complement factor h
EP3049079A4 (en) Solid forms of ceftolozane
HK1216839A1 (en) Modified release formulation
EP2994124A4 (en) INHIBITORS OF METALLO-ß-LACTAMASE-ENZYMES
EP2968698A4 (en) Compounds and compositions for drug release
EP3080137A4 (en) Prodrug for release of cisplatin and cyclooxygenase inhibitor
IL244752A0 (en) Compound for activating ampk and uses thereof
ZA201600025B (en) Tool for forming and releasing lashing
EP2959896A4 (en) Inhibitor of tprotein phosphorylation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/282 20060101ALI20170608BHEP

Ipc: A61P 31/00 20060101ALI20170608BHEP

Ipc: A61K 47/62 20170101ALI20170608BHEP

Ipc: A61K 47/55 20170101ALI20170608BHEP

Ipc: A61K 47/54 20170101ALI20170608BHEP

Ipc: C07F 15/00 20060101AFI20170608BHEP

Ipc: A61P 35/00 20060101ALI20170608BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170616

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180116